Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Tamir ShragaiMoshe E E GattNoa LavieIuliana VaxmanTamar TadmorOry RouvioMiri ZektserNethanel HorowitzHila MagenMouna BallanCelia SuruEfrat LuttwakShai LeviTomer Ziv-BaranIrit AviviYael C CohenPublished in: European journal of haematology (2020)
Our data support favorable safety tolerability and efficacy of daratumumab among non-selective RRAL patients in a real-world setting.